Cipla Ltd (Cipla) focuses on the research, development, production and commercialization of generic and branded therapies, and active pharmaceutical ingredients (APIs).

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Cipla focuses on making substantial investments and strengthening its research and development capabilities in APIs and formulations through innovative techniques. R&D is the key component of the company’s business continuity plans. Cipla’s R&D team comprises more than 300 scientists who strive to continuously develop new products in five R&D units in Maharashtra and Karnataka (India) and New York, USA. The company spent INR13,440 million on its R&D activities during FY2023, which as a percentage of revenue stood at 5.9% and grew 19.8% YoY. The company tracks the progress of priority projects and maintains healthy investments in the developmental pipeline which consists of more than 78 new products, including complex formulations. All the R&D centers are equipped with state-of-the-art infrastructure and have been accredited by international regulatory authorities namely USFDA, PMDA (Japan), EDQM (Europe), WHO, TGA (Australia) and KFDA (Korea). The company also invests in biosimilars segment through its subsidiary Cipla BioTec Pvt Ltd. In FY2023, Cipla launched 78 new products, filed 20 patents and 458 Drug Master Files (DMFs). Cipla has a cumulative total of 266 ANDAs/NDAs approvals; 1,704 DMFs approvals of which 150 are US DMFs and 303 granted patents.